A global trial is underway in Houston, Texas at the Texas Children’s Hospital that will test Epidiolex, and-based medicine, in children who have been diagnosed with a severe form of epilepsy known as Dravet Syndrome. The trial will be divided into two parts, the first will decide the dosage, and the second will decide whether or not the drug is efficient and safe to administer to children.
Epidiolex was created by England’s GW Pharmaceuticals and it is primarily composed of a highly concentrated form of CBD which exists only in marijuana plants. The drug contains zero, so there is no risk of the 30 test subjects catching an accidental “high.”
Dr. Angus Wilfong, a pediatric neurologist at Texas Children’s Hospital, was the first one to administer Epidiolex to patients and he is very optimistic. Wilfong has said that, “Initial trials of Epidiolex have shown promising signs of efficacy in children with treatment-resistant epilepsy and we are excited to be involved in research that will further determine if patients with Dravet syndrome will experience a reduction in their seizures. There are several extracts available from the cannabis plant that patients are trying, but with this trial, we are especially encouraged that Epidiolex does not contain any hallucinogenic or psychoactive components.”
Dravet syndrome is a terrible and debilitating disease that makes it nearly impossible for children to live an even remotely normal life. Dr. Gary Clark, the head of neurology at Texas Children’s hospital says, “We are hopeful that in the next year, the results of this trial will show this drug has a positive impact on enrolled patients and also that it will have implications for patients with other forms of intractable epilepsy.”
The introduction of a marijuana-based drug such as Epidiolex could change the future for anyone suffering from seizures.